Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-03

Last Posted Date: 2013-06-21

Lead Sponsor: NSABP Foundation Inc

Registration Number: NCT00002967

Locations: 🇺🇸
CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States
🇺🇸
York Hospital, York, Pennsylvania, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 105 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-09-01

Last Posted Date: 2017-02-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1970

Registration Number: NCT00002744

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸
Children's Hospital and Medical Center - Seattle, Seattle, Washington, United States

and more 31 locations

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2013-09-20

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 36

Registration Number: NCT00002616

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2010-10-01

Lead Sponsor: Temple University

Registration Number: NCT00002509

Locations: 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 50

Registration Number: NCT00002628

Locations: 🇺🇸
Methodist Hospital-Central Unit, Memphis, Tennessee, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-31

Last Posted Date: 2010-03-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002554

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002489

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002471

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-08-30

Last Posted Date: 2013-09-17

Lead Sponsor: Ottawa Regional Cancer Centre

Registration Number: NCT00002488

Locations: 🇨🇦
Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada
🇨🇦
Ottawa Regional Cancer Centre - Civic Campus, Ottawa, Ontario, Canada

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-26

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 2778

Registration Number: NCT00003519

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 131 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy